Assessment of Human DNA Vaccine Markets to 2028 by Mode of Administration, Application, End-user and Region

23 Jun 2023
www.prnewswire.com
VaccineClinical StudyEmergency Use AuthorizationDrug Approval
DUBLIN, June 23, 2023 /PRNewswire/ -- The "Human DNA Vaccine Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028 Segmented By Mode of Administration (Intramuscular, Subcutaneous, Intradermal, Others), By Application, By End User, By Region and Competition" report has been added to
ResearchAndMarkets.com's offering.
The global human DNA vaccine market is anticipated to observe impressive growth during the forecast period, 2024-2028, owing to the growing prevalence of cancer and infectious diseases in humans. An increase in the number of antibiotic-resistant pathogens is further expected to drive the growth of the human DNA Vaccine Market.
The growing prevalence of different diseases has significantly increased the demand for different types of vaccines. Additionally, growing research & development activities being initiated by various governments and pharmaceutical & biotechnology companies across the globe are further expected to create lucrative opportunities for the growth of the human DNA vaccine market in the coming years. In 2021, the research & development expenditure in the pharmaceutical industry across the globe was around USD238 billion.
Rise in Prevalence of Different Diseases
Globally, cancer is the leading cause of death. According to World Health Organization, around 50,550,287 cases of cancer prevalence have been reported worldwide in the last five years. This is due to the physical carcinogens, such as ultraviolet and ionizing radiation; chemical carcinogens, such as asbestos, components of tobacco smoke, alcohol, aflatoxin (a food contaminant), and arsenic (a drinking water contaminant) and biological carcinogens, such as infections from certain viruses, bacteria, or parasites as well as unhealthy lifestyle.
Cancer has become a global healthcare concern. The need to develop therapies for cancer is expected to support the growth of global human DNA vaccine market. Similarly, the increasing prevalence of diseases such as HIV, Human Papillomavirus, and Tuberculosis, which are deadly and require a potential treatment, is further expected to drive the growth of global human DNA vaccine market. As of 2021, globally, around 38.4 million people were living with HIV.
Increase in Number of Antibiotics Resistant Pathogens
Antibiotic resistance is one of the biggest threats to global health, food security, and development. The epidemiological models describe a direct relationship between antibiotic consumption and resistant pathogen. According to World Health Organization, 32 antibiotics were identified in clinical development, which addressed the top priority pathogens.
Some multi and resistant bacteria called "superbugs" that cause infections are not treatable with existing antimicrobial medicines such as antibiotics. Also, certain bacteria have developed resistance to existing treatment options, thereby creating a need to develop novel therapeutic solutions which can address the issue of antibiotic resistance. This, in turn, is expected to fuel the growth of Global Human DNA Vaccine Market.
Growth in R&D for DNA Vaccine
Rapid advancements in research and development (R&D) practices and activities are propelling the growth of the market on account of the growing need to develop novel human vaccines for the treatment of different life-threatening diseases. According to Clinicaltrials.gov, 247 clinical trials are in different phases of development across the globe for Human DNA vaccines. This clearly indicates that a lot of R&D is being done across the globe for developing human DNA vaccines for the treatment of different diseases, thereby supporting the growth of the global human DNA vaccine market.
Recent Developments
ZyCoV-D is a DNA plasmid-based COVID-19 vaccineCOVID-19 vaccine developed by Indian pharmaceutical company Cadila Healthcare, with support from the Biotechnology Industry Research Assistance Council in August 2021. This vaccine illustrated higher safety, efficacy, and immunogenicity.
The vaccine is administered into the skin without an injection and has been found to be 67% protective against symptomatic COVID-19 in clinical trials. ZyCoV-D is a three-dose intradermal vaccine applied using The PharmaJet needle-free system, Tropis, which can significantly reduce any side effects and improve quality. Zydus CadilaZydus Cadila has received approval for Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D.
Report Scope
In this report, Global Human DNA Vaccine Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below.
Human DNA Vaccine Market, by Mode of Administration
Intramuscular
Subcutaneous
Intradermal
Others
Human DNA Vaccine Market, by Application
Oncology
HIV
Human Papillomavirus
Others
Human DNA Vaccine Market, by End-user
Hospitals & Clinics
Biotechnology & Pharmaceutical Companies
Academic & Research Institutions
Others
Human DNA Vaccine Market, by Region
North America
Europe
Asia-Pacific
South America
Middle East & Africa
Competitive Landscape
Detailed analysis of the major companies present in Global Human DNA Vaccine market. A selection of companies mentioned in this report includes:
BOEHRINGER INGELHEIM GmbH (Merial)
ELI-LILLY (Novartis Animal Health)
Gene One Life Science
ZOETIS INC. (Fort dodge Animal Health)
For more information about this report visit https://www.researchandmarkets.com/r/2h19r7
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.